A detailed history of High Tower Advisors, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 33,224 shares of IMVT stock, worth $913,992. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,224
Previous 25,965 27.96%
Holding current value
$913,992
Previous $685,000 33.28%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$27.51 - $27.51 $199,695 - $199,695
7,259 Added 27.96%
33,224 $913,000
Q2 2024

Aug 13, 2024

SELL
$25.1 - $31.61 $34,612 - $43,590
-1,379 Reduced 5.04%
25,965 $685,000
Q1 2024

May 06, 2024

BUY
$30.27 - $43.79 $635 - $919
21 Added 0.08%
27,344 $883,000
Q4 2023

Feb 12, 2024

BUY
$31.31 - $44.19 $93,930 - $132,570
3,000 Added 12.33%
27,323 $1.15 Million
Q3 2023

Nov 08, 2023

BUY
$18.55 - $39.96 $1,409 - $3,036
76 Added 0.31%
24,323 $933,000
Q4 2021

Feb 10, 2022

BUY
$7.33 - $9.32 $177,730 - $225,982
24,247 New
24,247 $206,000
Q1 2021

May 10, 2021

SELL
$13.08 - $49.6 $60,168 - $228,160
-4,600 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$36.36 - $52.71 $167,256 - $242,466
4,600 New
4,600 $209,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.